PER-020-19招募中未知
ACCEPTABILITY, TOLERABILITY, AND ADHERENCE OF THREE RECTAL MICROBICIDE PLACEBO FORMULATIONS AMONG HIV SERONEGATIVE CISGENDER MEN, TRANSGENDER MEN AND TRANSGENDER WOMEN WHO ENGAGE IN RECEPTIVE ANAL INTERCOURSE
INSTITUTO NACIONAL DE ALERGIAS Y ENFERMEDADES INFECCIOSAS DE LOS ESTADOS UNIDOS,0 个研究点目标入组 30 人开始时间: 2019年8月14日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Individuals who meet the following criteria are eligible for study inclusion:
- •1.Men (cis or transgender) and TGW who are 18-35 years old at Screening, verified per site SOP
- •2.Able and willing to provide written informed consent
- •3.HIV-1/2 uninfected at Screening and Enrollment, per applicable algorithm in Appendix II and willing to receive HIV test results
- •4.Able and willing to provide adequate locator information, as defined in site SOP
- •5.Available to return for all study visits and willing to comply with study participation requirements
- •6.In general good health at Screening and Enrollment, as determined by the site Investigator of Record (IoR) or designee
- •7.At Screening, history of consensual RAI at least three times in the past three months and expecting to maintain at least this frequency of RAI during study participation per participant report
- •8.Willing to not take part in other research studies involving drugs, medical devices, genital or rectal products, or vaccines for the duration of study participation (including the time between Screening and Enrollment)
- •9.For individuals who can get pregnant (i.e., TGM with a female reproductive system): a negative pregnancy test at Screening and Enrollment
- •10.For individuals who can get pregnant: Per participant report at Enrollment, using an effective method of contraception for at least 30 days (inclusive) prior to Enrollment and intending to use an effective method for the duration of study participation; effective methods include:
- •a)Hormonal methods
- •b)Intrauterine device (IUD) inserted at least 30 days prior to Enrollment (but not past the maximum length of recommended usage according to package instructions)
- •c)Sterilization (of participant or, if in a monogamous relationship, of partner, as defined in site SOPs)
- •d)Abstinence from RVI for 90 days prior to Enrollment, and intention to abstain from RVI for the duration of study participation
排除标准
- •Individuals who meet any of the following criteria will be excluded from the study:
- •1.At Screening:
- •a)History of inflammatory bowel disease
- •b)Current anorectal condition that would impede product placement or assessment of tolerability by participant report or exam
- •2.Anticipated use and/or unwillingness to abstain from using non-study rectally- administered medications and products during study participation, including personal lubricants containing nonoxynol-9 (N-9)
- •Note: The use of non-study personal lubricants and usual pre-RAI douches that do not contain N-9 is permitted during study participation.
- •3.Known adverse reaction to any of the components of the study products
- •4.Participation in research studies involving drugs, medical devices, genital products, or vaccines within 30 days of the Enrollment Visit
- •5.Participation in research studies involving rectal products (ever)
- •6.Per participant report, use of post-exposure prophylaxis (PEP) for potential HIV exposure within the 3 months prior to Enrollment
- •7.In the 3 months prior to Enrollment, participant engagement in condomless RAI or RVI while not on PrEP with a partner who is HIV-positive and either not on ART or of unknown ART use status (by self-report)
- •8.In the month prior to Enrollment, participant engagement in condomless RAI or RVI while not on PrEP with a partner who is of unknown HIV status and unknown PrEP/ART use status (by self-report)
- •9.Non-therapeutic injection drug use in the 12 months prior to Enrollment
- •10.At either Screening or Enrollment, participant-reported symptoms and/or clinical or laboratory diagnosis of active anorectal or reproductive tract infection (RTI) requiringtreatmentpercurrentWHOguidelines (http://www.who.int/hiv/pub/sti/pub6/en/), or symptomatic urinary tract infection (UTI). Infections requiring treatment include Neisseria gonorrhea (GC), Chlamydia trachomatis (CT), syphilis, active herpes simplex virus (HSV) lesions, anogenital sores or ulcers, or symptomatic genital warts, chancroid, pelvic inflammatory disease (PID), symptomatic bacterial vaginosis (BV), symptomatic vaginal candidiasis, and trichomoniasis.
- •Note: Otherwise eligible participants with a symptomatic UTI or an STI/RTI requiring treatment per current WHO guidelines may be re-tested during the screening process and if treatment is completed and symptoms have resolved within the screening window the participant may be enrolled.
- •Note: HSV-1 or HSV-2 seropositive diagnosis with no active lesions is permitted since treatment is not required.
- •11.For individuals who can get pregnant: Pregnant or breastfeeding at either Screening or Enrollment or planning to become pregnant during study participation
- •12.For individuals who can get pregnant: Last pregnancy outcome 90 days or less prior to Screening
- •13.Has any other condition that, in the opinion of the IoR/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives.
研究者
相似试验
招募中
3 期
Clinical study of Ayurvedic intervention – Punarnavadi Mandura in treating Iron Deficiency Anemia.CTRI/2023/05/053299CENTRAL COUNCIL FOR RESEARCH IN AYURVEDIC SCIENCES Ministry of AYUSH
进行中（未招募）
不适用
Evaluation de la tolérance et de l’acceptabilité de la Rasagiline dans le traitement de la maladie de Parkinson au stade précoce - ACTORMaladie de Parkinson idiopathique au stade précoceMaladie de Parkinson, numéro de classification MedDRA 10061536EUCTR2007-007397-28-FRQualissima
尚未招募
Unknown
Designing and piloting an innovative mixed reality experience to deliver exposure therapy for contamination-related obsessive-compulsive disorderMental Health - AnxietyMental Health - Other mental health disordersObsessive-Compulsive DisorderACTRN12624000881538Swinburne University of Technology20
已完成
不适用
To evaluate the acceptability, adherence, affordability and efficacy of carbohydrate-restricted diets in the treatment of obesity in children.ObesityACTRN12616001640493AUT University25
尚未招募
4 期
Treatment for knee joint Osteo Arthritis in AyurvedaCTRI/2023/07/055131Central council for research in ayurvedic science